<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38784593</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2296-2565</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in public health</Title><ISOAbbreviation>Front Public Health</ISOAbbreviation></Journal><ArticleTitle>Clinical and serological predictors of post COVID-19 condition-findings from a Canadian prospective cohort study.</ArticleTitle><Pagination><StartPage>1276391</StartPage><MedlinePgn>1276391</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1276391</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpubh.2024.1276391</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">More than 3&#x2009;years into the pandemic, there is persisting uncertainty as to the etiology, biomarkers, and risk factors of Post COVID-19 Condition (PCC). Serological research data remain a largely untapped resource. Few studies have investigated the potential relationships between post-acute serology and PCC, while accounting for clinical covariates.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We compared clinical and serological predictors among COVID-19 survivors with (<i>n</i>&#x2009;=&#x2009;102 cases) and without (<i>n</i>&#x2009;=&#x2009;122 controls) persistent symptoms &#x2265;12&#x2009;weeks post-infection. We selected four primary serological predictors (anti-nucleocapsid (N), anti-Spike, and anti-receptor binding domain (RBD) IgG titres, and neutralization efficiency), and specified clinical covariates <i>a priori</i>.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Similar proportions of PCC-cases (66.7%, <i>n</i>&#x2009;=&#x2009;68) and infected-controls (71.3%, <i>n</i>&#x2009;=&#x2009;87) tested positive for anti-N IgG. More cases tested positive for anti-Spike (94.1%, <i>n</i>&#x2009;=&#x2009;96) and anti-RBD (95.1%, <i>n</i>&#x2009;=&#x2009;97) IgG, as compared with controls (anti-Spike: 89.3%, <i>n</i>&#x2009;=&#x2009;109; anti-RBD: 84.4%, <i>n</i>&#x2009;=&#x2009;103). Similar trends were observed among unvaccinated participants. Effects of IgG titres on PCC status were non-significant in univariate and multivariate analyses. Adjusting for age and sex, PCC-cases were more likely to be efficient neutralizers (OR 2.2, 95% CI 1.11-4.49), and odds was further increased among cases to report deterioration in quality of life (OR 3.4, 95% CI 1.64-7.31). Clinical covariates found to be significantly related to PCC included obesity (OR 2.3, <i>p</i>&#x2009;=&#x2009;0.02), number of months post COVID-19 (OR 1.1, <i>p</i>&#x2009;&lt;&#x2009;0.01), allergies (OR 1.8, <i>p</i>&#x2009;=&#x2009;0.04), and need for medical support (OR 4.1, <i>p</i>&#x2009;&lt;&#x2009;0.01).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Despite past COVID-19 infection, approximately one third of PCC-cases and infected-controls were seronegative for anti-N IgG. Findings suggest higher neutralization efficiency among cases as compared with controls, and that this relationship is stronger among cases with more severe PCC. Cases also required more medical support for COVID-19 symptoms, and described complex, ongoing health sequelae. More data from larger cohorts are needed to substantiate results, permit subgroup analyses of IgG titres, and explore for differences between clusters of PCC symptoms. Future assessment of IgG subtypes may also elucidate new findings.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Collins, Galipeau, Arnold, Bh&#xe9;reur, Booth, Buchan, Cooper, Crawley, McCluskie, McGuinty, Pelchat, Rocheleau, Saginur, Gravel, Hawken, Langlois and Little.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Erin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galipeau</LastName><ForeName>Yannick</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Corey</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bh&#xe9;reur</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Montreal, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Booth</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buchan</LastName><ForeName>Arianne C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Ottawa Hospital Research Institute, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Curtis</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Ottawa Hospital Research Institute, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Coronavirus Variants Rapid Response Network (CoVaRR-Net), Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Infection, Immunity and Inflammation (CI3), University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crawley</LastName><ForeName>Angela M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Coronavirus Variants Rapid Response Network (CoVaRR-Net), Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Infection, Immunity and Inflammation (CI3), University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCluskie</LastName><ForeName>Pauline S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGuinty</LastName><ForeName>Michaeline</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Ottawa Hospital Research Institute, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pelchat</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocheleau</LastName><ForeName>Lynda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saginur</LastName><ForeName>Raphael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Ottawa Hospital Research Institute, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ottawa Health Science Network Research Ethics Board (OHSN-REB), Ottawa Hospital Research Institute, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gravel</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Mathematics and Statistics, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hawken</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langlois</LastName><ForeName>Marc-Andr&#xe9;</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Coronavirus Variants Rapid Response Network (CoVaRR-Net), Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Infection, Immunity and Inflammation (CI3), University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Little</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Coronavirus Variants Rapid Response Network (CoVaRR-Net), Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Knowledge Synthesis and Application Unit (KSAU), University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Public Health</MedlineTA><NlmUniqueID>101616579</NlmUniqueID><ISSNLinking>2296-2565</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">IgG</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibodies</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">neutralization</Keyword><Keyword MajorTopicYN="N">post COVID-19 condition</Keyword><Keyword MajorTopicYN="N">serology</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>24</Day><Hour>3</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38784593</ArticleId><ArticleId IdType="pmc">PMC11111987</ArticleId><ArticleId IdType="doi">10.3389/fpubh.2024.1276391</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>CDC . COVID-19 and Your Health. Centers for Disease Control and Prevention. (2022). Available at:
https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html (Accessed December 16, 2022).</Citation></Reference><Reference><Citation>Canada PHA . Post-COVID-19 condition (long COVID). (2021). https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/symptoms/post-covid-19-condition.html (Accessed on August 20, 2021).</Citation></Reference><Reference><Citation>Solve Long COVID Initiative . Long Covid impact on adult Americans: early indicators estimating prevalence and cost. Solve Long COVID Initiative, April 5. (2022). Available at:
https://solvecfs.org/wp-content/uploads/2022/04/Long_Covid_Impact_Paper.pdf (Accessed April 5, 2022).</Citation></Reference><Reference><Citation>Government of Canada SC . Canadian COVID-19 Antibody and Health Survey (CCAHS). (2022). Available at: https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&amp;SDDS=5339 (Accessed October 13, 2022).</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. (2023) 21:133&#x2013;46. doi: 10.1038/s41579-022-00846-2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Infectious Diseases and Clinical Care . Understanding the Post COVID-19 Condition (Long COVID) in Adults and the Expected Burden for Ontario. Ontario COVID-19 Science Advisory Table. (2022).</Citation></Reference><Reference><Citation>Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C, et al. . Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. (2022) 54:1473&#x2013;87. doi: 10.1080/07853890.2022.2076901, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2076901</ArticleId><ArticleId IdType="pmc">PMC9132392</ArticleId><ArticleId IdType="pubmed">35594336</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, Safarpour A, Lunz Trujillo K, Simonson MD, et al. . Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open. (2022) 5:e2238804&#x2013;4. doi: 10.1001/jamanetworkopen.2022.38804, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.38804</ArticleId><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Government of Canada . Post-COVID-19 Condition in Canada: What we know, what we don&#x2019;t know, and a framework for action. (2022). Available at:
https://science.gc.ca/site/science/en/office-chief-science-advisor/initiatives-covid-19/post-covid-19-condition-canada-what-we-know-what-we-dont-know-and-framework-action (Accessed May 17, 2023).</Citation></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post COVID-19 condition or long COVID: a Meta-analysis and systematic review. J Infect Dis. (2022) 226:jiac136: 1593&#x2013;607. doi: 10.1093/infdis/jiac136, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, et al. . Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA. (2022) 328:676&#x2013;8. doi: 10.1001/jama.2022.11691, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.11691</ArticleId><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C, Notarte KI, Peligro PJ, Velasco JV, Ocampo MJ, Henry BM, et al. . Long-COVID symptoms in individuals infected with different SARS-CoV-2 variants of concern: a systematic review of the literature. Viruses. (2022) 14:629. doi: 10.3390/v14122629, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14122629</ArticleId><ArticleId IdType="pmc">PMC9785120</ArticleId><ArticleId IdType="pubmed">36560633</ArticleId></ArticleIdList></Reference><Reference><Citation>Byambasuren O, Stehlik P, Clark J, Alcorn K, Glasziou P. Effect of covid-19 vaccination on long covid: systematic review. BMJ Med. (2023) 2:e000385. doi: 10.1136/bmjmed-2022-000385, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2022-000385</ArticleId><ArticleId IdType="pmc">PMC9978692</ArticleId><ArticleId IdType="pubmed">36936268</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, Catahay JA, Velasco JV, Pastrana A, ver AT, Pangilinan FC, et al. . Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. eClinicalMedicine. (2022) 53:101624. doi: 10.1016/j.eclinm.2022.101624, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit D, Nicholson TR, Needham DM, Seylanova N, Parr C, Chen J, et al. . Studying the post-COVID-19 condition: research challenges, strategies, and importance of Core outcome set development. BMC Med. (2022) 20:50&#x2013;13. doi: 10.1186/s12916-021-02222-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02222-y</ArticleId><ArticleId IdType="pmc">PMC8813480</ArticleId><ArticleId IdType="pubmed">35114994</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C, Zurbuchen Y, Taeschler P, Ballouz T, Menges D, Hasler S, et al. . Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun. (2022) 13:446&#x2013;12. doi: 10.1038/s41467-021-27797-1, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27797-1</ArticleId><ArticleId IdType="pmc">PMC8789854</ArticleId><ArticleId IdType="pubmed">35078982</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight DRT, Munipalli B, Logvinov II, Halkar MG, Mitri G, Dabrh AMA, et al. . Perception, prevalence, and prediction of severe infection and post-acute sequelae of COVID-19. Am J Med Sci. (2022) 363:295&#x2013;304. doi: 10.1016/j.amjms.2022.01.002, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjms.2022.01.002</ArticleId><ArticleId IdType="pmc">PMC8743283</ArticleId><ArticleId IdType="pubmed">35016849</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabbri A, Voza A, Riccardi A, Vanni S, De Iaco F. Unfavorable outcome and long-term sequelae in cases with severe COVID-19. Viruses. (2023) 15:485. doi: 10.3390/v15020485, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15020485</ArticleId><ArticleId IdType="pmc">PMC9959293</ArticleId><ArticleId IdType="pubmed">36851699</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, et al. . Risk factors associated with post&#x2212;COVID-19 condition: a systematic review and Meta-analysis. JAMA Intern Med. (2023) 183:566&#x2013;80. doi: 10.1001/jamainternmed.2023.0750, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0750</ArticleId><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia X, Cao S, Lee AS, Manohar M, Sindher SB, Ahuja N, et al. . Anti-nucleocapsid antibody levels and pulmonary comorbid conditions are linked to post&#x2013;COVID-19 syndrome. JCI Insight. (2022) 7:713. doi: 10.1172/jci.insight.156713, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.156713</ArticleId><ArticleId IdType="pmc">PMC9310538</ArticleId><ArticleId IdType="pubmed">35801588</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishna BA, Lim EY, Mactavous L, Lyons PA, Doffinger R, Bradley JR, et al. . Evidence of previous SARS-CoV-2 infection in seronegative patients with long COVID. EBioMedicine. (2022) 81:104129. doi: 10.1016/j.ebiom.2022.104129, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104129</ArticleId><ArticleId IdType="pmc">PMC9235296</ArticleId><ArticleId IdType="pubmed">35772216</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n J, Padilla S, Fern&#xe1;ndez-Gonz&#xe1;lez M, Garc&#xed;a JA, Agull&#xf3; V, Andreo M, et al. . Antibody response to SARS-CoV-2 is associated with long-term clinical outcome in patients with COVID-19: a longitudinal study. J Clin Immunol. (2021) 41:1490&#x2013;501. doi: 10.1007/s10875-021-01083-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01083-7</ArticleId><ArticleId IdType="pmc">PMC8285689</ArticleId><ArticleId IdType="pubmed">34273064</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. . Evolution of antibody immunity to SARS-CoV-2. Nature. (2021) 591:639&#x2013;44. doi: 10.1038/s41586-021-03207-w, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, Mohn KGI, Brokstad KA, Zhou F, Linchausen DW, Hansen BA, et al. . Long COVID in a prospective cohort of home-isolated patients. Nat Med. (2021) 27:1607&#x2013;13. doi: 10.1038/s41591-021-01433-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n J, Fern&#xe1;ndez M, Padilla S, Garc&#xed;a JA, Agull&#xf3; V, Lozano V, et al. . Immunologic phenotype of patients with long-COVID syndrome of 1-year duration. Front Immunol. (2022) 13:13. doi: 10.3389/fimmu.2022.920627, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.920627</ArticleId><ArticleId IdType="pmc">PMC9451924</ArticleId><ArticleId IdType="pubmed">36090973</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerhards C, Thiaucourt M, Kittel M, Becker C, Ast V, Hetjens M, et al. . Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection. Int J Infect Dis. (2021) 107:221&#x2013;7. doi: 10.1016/j.ijid.2021.04.080</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.04.080</ArticleId><ArticleId IdType="pmc">PMC8080496</ArticleId><ArticleId IdType="pubmed">33932604</ArticleId></ArticleIdList></Reference><Reference><Citation>Lier J, Stoll K, Obrig H, Baum P, Deterding L, Bernsdorff N, et al. . Neuropsychiatric phenotype of post COVID-19 syndrome in non-hospitalized patients. Front Neurol. (2022) 13:13. doi: 10.3389/fneur.2022.988359, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2022.988359</ArticleId><ArticleId IdType="pmc">PMC9552839</ArticleId><ArticleId IdType="pubmed">36237627</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. . Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health. (2021) 6:100122. doi: 10.1016/j.lanepe.2021.100122, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld MS, Peluso MJ, Kelly JD, Win S, Swaminathan S, Li D, et al. . Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection. JCI Insight. (2022) 7:7053. doi: 10.1172/jci.insight.157053, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.157053</ArticleId><ArticleId IdType="pmc">PMC9220849</ArticleId><ArticleId IdType="pubmed">35389890</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins E, Galipeau Y, Arnold C, Bosveld C, Heiskanen A, Keeshan A, et al. . Cohort profile: stop the spread Ottawa (SSO)&#x2013;a community-based prospective cohort study on antibody responses, antibody neutralisation efficiency and cellular immunity to SARS-CoV-2 infection and vaccination. BMJ Open. (2022) 12:e062187. doi: 10.1136/bmjopen-2022-062187, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-062187</ArticleId><ArticleId IdType="pmc">PMC9461086</ArticleId><ArticleId IdType="pubmed">36691221</ArticleId></ArticleIdList></Reference><Reference><Citation>Colwill K, Galipeau Y, Stuible M, Gervais C, Arnold C, Rathod B, et al. . A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination. Clin Trans Immunol. (2022) 11:e1380. doi: 10.1002/cti2.1380, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1380</ArticleId><ArticleId IdType="pmc">PMC8942165</ArticleId><ArticleId IdType="pubmed">35356067</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler RC, Andrews G, Colpe LJ, Hiripi E, Mroczek DK, Normand SLT, et al. . Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med. (2002) 32:959&#x2013;76. doi: 10.1017/S0033291702006074, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291702006074</ArticleId><ArticleId IdType="pubmed">12214795</ArticleId></ArticleIdList></Reference><Reference><Citation>Horowitz M, Wilner N, Alvarez W. Impact of event scale: a measure of subjective stress. Psychosom Med. (1979) 41:209&#x2013;18. doi: 10.1097/00006842-197905000-00004, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006842-197905000-00004</ArticleId><ArticleId IdType="pubmed">472086</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrell FE. Regression modeling strategies. 2nd ed. Berlin, Germany: Springer; (2015).</Citation></Reference><Reference><Citation>Layton AT, Sadria M. Understanding the dynamics of SARS-CoV-2 variants of concern in Ontario, Canada: a modeling study. Sci Rep. (2022) 12:2114&#x2013;6. doi: 10.1038/s41598-022-06159-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-06159-x</ArticleId><ArticleId IdType="pmc">PMC8826311</ArticleId><ArticleId IdType="pubmed">35136161</ArticleId></ArticleIdList></Reference><Reference><Citation>Ontario Dashboard . Ontario COVID-19 science advisory table. (2022). Available at:
https://covid19-sciencetable.ca/ontario-dashboard/ (Accessed September 8, 2022).</Citation></Reference><Reference><Citation>van Elslande J, Oyaert M, Lorent N, Vande Weygaerde Y, van Pottelbergh G, Godderis L, et al. . Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection. Diagn Microbiol Infect Dis. (2022) 103:115659. doi: 10.1016/j.diagmicrobio.2022.115659, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diagmicrobio.2022.115659</ArticleId><ArticleId IdType="pmc">PMC8837483</ArticleId><ArticleId IdType="pubmed">35278794</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Hoogen LL, Smits G, Van Hagen CCE, Wong D, Vos ERA, van Boven M, et al. . Seropositivity to nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: a complementary tool to detect breakthrough infections after COVID-19 vaccination? Vaccine. (2022) 40:2251&#x2013;7. doi: 10.1016/j.vaccine.2022.03.009, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.03.009</ArticleId><ArticleId IdType="pmc">PMC8904156</ArticleId><ArticleId IdType="pubmed">35287986</ArticleId></ArticleIdList></Reference><Reference><Citation>Krutikov M, Palmer T, Tut G, Fuller C, Azmi B, Giddings R, et al. . Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England. Lancet Healthy Longevity. (2022) 3:e13&#x2013;21. doi: 10.1016/S2666-7568(21)00282-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(21)00282-8</ArticleId><ArticleId IdType="pmc">PMC8676418</ArticleId><ArticleId IdType="pubmed">34935001</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker HJ, Gower C, Otter AD, Simmons R, Kirsebom F, Letley L, et al. . Nucleocapsid antibody positivity as a marker of past SARS-CoV-2 infection in population serosurveillance studies: impact of variant, vaccination, and choice of assay cut-off. medRxiv. (2021) 2021:64964. doi: 10.1101/2021.10.25.21264964</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.10.25.21264964</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. . Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study. Clin Infect Dis. (2022) 74:1191&#x2013;8. doi: 10.1093/cid/ciab611, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Lu S, Tang AF, Durstenfeld MS, Ho HE, Goldberg SA, et al. . Markers of immune activation and inflammation in individuals with Postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. (2021) 224:1839&#x2013;48. doi: 10.1093/infdis/jiab490, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozonoff A, Schaenman J, Jayavelu ND, Milliren CE, Calfee CS, Cairns CB, et al. . Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: results from the IMPACC study. EBioMedicine. (2022) 83:104208. doi: 10.1016/j.ebiom.2022.104208, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104208</ArticleId><ArticleId IdType="pmc">PMC9359694</ArticleId><ArticleId IdType="pubmed">35952496</ArticleId></ArticleIdList></Reference><Reference><Citation>Sancilio A, Schrock JM, Demonbreun AR, D&#x2019;Aquila RT, Mustanski B, Vaught LA, et al. . COVID-19 symptom severity predicts neutralizing antibody activity in a community-based serological study. Sci Rep. (2022) 12:12269&#x2013;7. doi: 10.1038/s41598-022-15791-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-15791-6</ArticleId><ArticleId IdType="pmc">PMC9293881</ArticleId><ArticleId IdType="pubmed">35851303</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, et al. . COVID-19-neutralizing antibodies predict disease severity and survival. Cell. (2021) 184:476&#x2013;488.e11. doi: 10.1016/j.cell.2020.12.015, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.12.015</ArticleId><ArticleId IdType="pmc">PMC7837114</ArticleId><ArticleId IdType="pubmed">33412089</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, To KKW, Chan KH, Wong YC, Zhou R, Kwan KY, et al. . High neutralizing antibody titer in intensive care unit patients with COVID-19. Emerg. Microbes Infect. (2020) 9:1664&#x2013;70. doi: 10.1080/22221751.2020.1791738, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1791738</ArticleId><ArticleId IdType="pmc">PMC7473321</ArticleId><ArticleId IdType="pubmed">32618497</ArticleId></ArticleIdList></Reference><Reference><Citation>Batiha GES, Al-kuraishy HM, Al-Gareeb AI, Welson NN. Pathophysiology of post-COVID syndromes: a new perspective. Virol J. (2022) 19:158&#x2013;20. doi: 10.1186/s12985-022-01891-2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01891-2</ArticleId><ArticleId IdType="pmc">PMC9548310</ArticleId><ArticleId IdType="pubmed">36210445</ArticleId></ArticleIdList></Reference><Reference><Citation>Buck AM, Deitchman AN, Takahashi S, Lu S, Goldberg SA, Hoh R, et al. . The breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of long COVID symptoms. medRxiv. (2023) 2023:7923. doi: 10.1101/2023.03.30.23287923, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.03.30.23287923</ArticleId><ArticleId IdType="pmc">PMC10754238</ArticleId><ArticleId IdType="pubmed">37988251</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. (2020) 100:327&#x2013;32. doi: 10.1016/j.ijid.2020.09.016, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7529115</ArticleId><ArticleId IdType="pubmed">32920235</ArticleId></ArticleIdList></Reference><Reference><Citation>Osmanov IM, Spiridonova E, Bobkova P, Gamirova A, Shikhaleva A, Andreeva M, et al. . Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC global follow-up protocol: a prospective cohort study. Eur Respir J. (2022) 59:2101341. doi: 10.1183/13993003.01341-2021, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01341-2021</ArticleId><ArticleId IdType="pmc">PMC8576804</ArticleId><ArticleId IdType="pubmed">34210789</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostev K, Smith L, Koyanagi A, Konrad M, Jacob L. Post-COVID-19 conditions in children and adolescents diagnosed with COVID-19. Pediatr Res. (2022) 95:182&#x2013;7. doi: 10.1038/s41390-022-02111-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41390-022-02111-x</ArticleId><ArticleId IdType="pmc">PMC9107066</ArticleId><ArticleId IdType="pubmed">35568733</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs ET, Catalfamo CJ, Colombo PM, Khan SM, Austhof E, Cordova-Marks F, et al. . Pre-existing conditions associated with post-acute sequelae of COVID-19. J Autoimmun. (2023) 135:102991. doi: 10.1016/j.jaut.2022.102991, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2022.102991</ArticleId><ArticleId IdType="pmc">PMC9816074</ArticleId><ArticleId IdType="pubmed">36634460</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell ML, Catalfamo CJ, Farland LV, Ernst KC, Jacobs ET, Klimentidis YC, et al. . Post-acute sequelae of COVID-19 in a non-hospitalized cohort: results from the Arizona CoVHORT. PLoS One. (2021) 16:e0254347. doi: 10.1371/journal.pone.0254347, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0254347</ArticleId><ArticleId IdType="pmc">PMC8336814</ArticleId><ArticleId IdType="pubmed">34347785</ArticleId></ArticleIdList></Reference><Reference><Citation>Santhosh L, Block B, Kim SY, Raju S, Shah RJ, Thakur N, et al. . Rapid design and implementation of post-COVID-19 clinics. Chest. (2021) 160:671&#x2013;7. doi: 10.1016/j.chest.2021.03.044, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2021.03.044</ArticleId><ArticleId IdType="pmc">PMC8010340</ArticleId><ArticleId IdType="pubmed">33811910</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim Mohamed HM, Atya M, Ahmed G, Abdelmohsen S, Sobhy K, Hussein A. Telehealth program: effect of physiotherapy intervention on dyspnea, fatigue and functional status of post COVID-19 syndrome patients. Assiut Sci Nurs J. (2022) 10:265&#x2013;80. doi: 10.21608/asnj.2022.167006.1437</Citation><ArticleIdList><ArticleId IdType="doi">10.21608/asnj.2022.167006.1437</ArticleId></ArticleIdList></Reference><Reference><Citation>Houben S, Bonnech&#xe8;re B. The impact of COVID-19 infection on cognitive function and the implication for rehabilitation: a systematic review and Meta-analysis. Int J Environ Res Public Health. (2022) 19:7748. doi: 10.3390/ijerph19137748, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19137748</ArticleId><ArticleId IdType="pmc">PMC9266128</ArticleId><ArticleId IdType="pubmed">35805406</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg A, Subramain M, Barlow PB, Garvin L, Hoth KF, Dukes K, et al. . Patient experiences with a tertiary care post-COVID-19 clinic. J Patient Exp. (2023) 10:11515. doi: 10.1177/23743735231151539, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/23743735231151539</ArticleId><ArticleId IdType="pmc">PMC9869203</ArticleId><ArticleId IdType="pubmed">36698619</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowakowski S, Kokonda M, Sultana R, Duong BB, Nagy SE, Zaidan MF, et al. . Association between sleep quality and mental health among patients at a post-COVID-19 recovery clinic. Brain Sci. (2022) 12:586. doi: 10.3390/brainsci12050586, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci12050586</ArticleId><ArticleId IdType="pmc">PMC9139253</ArticleId><ArticleId IdType="pubmed">35624973</ArticleId></ArticleIdList></Reference><Reference><Citation>Levan S, Mourad M, Block B, Shah R, Santhosh L. Impact of a multidisciplinary post-COVID-19 clinic on hospital admissions and ED visits. Chest. (2023) 164:S0012369223000090: 199&#x2013;202. doi: 10.1016/j.chest.2022.12.031, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2022.12.031</ArticleId><ArticleId IdType="pmc">PMC9811943</ArticleId><ArticleId IdType="pubmed">36610666</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotb N, Barreto L, Janaudis-Ferreira T. Post-exertional malaise in pulmonary rehabilitation after COVID-19: are we not giving enough attention? Canad J Respir Crit Care Sleep Med. (2023) 7:93&#x2013;118. doi: 10.1080/24745332.2022.2150722</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/24745332.2022.2150722</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, Cha MJ, Choi H, Kim MC, Chung JW, Lee KS, et al. . Relationship between SARS-CoV-2 antibody titer and the severity of COVID-19. J Microbiol Immunol Infect. (2022) 55:1094&#x2013;100. doi: 10.1016/j.jmii.2022.04.005, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2022.04.005</ArticleId><ArticleId IdType="pmc">PMC9069977</ArticleId><ArticleId IdType="pubmed">35570185</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan X, Chen G, Jin Z, Zhang Z, Zhang B, He J, et al. . Anti-SARS-CoV-2 IgG levels in relation to disease severity of COVID-19. J Med Virol. (2022) 94:380&#x2013;3. doi: 10.1002/jmv.27274, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27274</ArticleId><ArticleId IdType="pmc">PMC8426683</ArticleId><ArticleId IdType="pubmed">34403142</ArticleId></ArticleIdList></Reference><Reference><Citation>Basharat S, Chao YS, McGill SC. Subtypes of post&#x2013;COVID-19 condition: a review of the emerging evidence. cjht. (2022) 2:516. doi: 10.51731/cjht.2022.516</Citation><ArticleIdList><ArticleId IdType="doi">10.51731/cjht.2022.516</ArticleId><ArticleId IdType="pubmed">38507533</ArticleId></ArticleIdList></Reference><Reference><Citation>Molnar T, Varnai R, Schranz D, Zavori L, Peterfi Z, Sipos D, et al. . Severe fatigue and memory impairment are associated with lower serum level of anti-SARS-CoV-2 antibodies in patients with post-COVID symptoms. J Clin Med. (2021) 10:4337. doi: 10.3390/jcm10194337, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10194337</ArticleId><ArticleId IdType="pmc">PMC8509483</ArticleId><ArticleId IdType="pubmed">34640355</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. . Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. (2022) 185:881&#x2013;895.e20. doi: 10.1016/j.cell.2022.01.014, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, et al. . Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. (2023) 23:556&#x2013;67. doi: 10.1016/S1473-3099(22)00801-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00801-5</ArticleId><ArticleId IdType="pmc">PMC10014083</ArticleId><ArticleId IdType="pubmed">36681084</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidarsson G, Dekkers G, Rispens T. IgG subclasses and Allotypes: from structure to effector functions. Front Immunol. (2014) 5:5. doi: 10.3389/fimmu.2014.00520, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00520</ArticleId><ArticleId IdType="pmc">PMC4202688</ArticleId><ArticleId IdType="pubmed">25368619</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates JL, Ehrbar DJ, Hunt DT, Girardin RC, Dupuis AP, Payne AF, et al. . Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity. Cell Rep Med. (2021) 2:100329. doi: 10.1016/j.xcrm.2021.100329, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100329</ArticleId><ArticleId IdType="pmc">PMC8205277</ArticleId><ArticleId IdType="pubmed">34151306</ArticleId></ArticleIdList></Reference><Reference><Citation>Korobova ZR, Zueva EV, Arsentieva NA, Batsunov OK, Liubimova NE, Khamitova IV, et al. . Changes in anti-SARS-CoV-2 IgG subclasses over time and in association with disease severity. Viruses. (2022) 14:941. doi: 10.3390/v14050941, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14050941</ArticleId><ArticleId IdType="pmc">PMC9143443</ArticleId><ArticleId IdType="pubmed">35632683</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo H, Jia T, Chen J, Li X, Zhang R, Sun C. The characterization of disease severity associated IgG subclasses response in COVID-19 patients. Front Immunol. (2021) 12:632814. doi: 10.3389/fimmu.2021.632814, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.632814</ArticleId><ArticleId IdType="pmc">PMC7982848</ArticleId><ArticleId IdType="pubmed">33763078</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel J, Walter AJ, Gl&#xfc;ck V, et al. . IgG4 serum levels are not elevated in cases of post-COVID syndrome. bioRxiv. (2023) 2023:454. doi: 10.1101/2023.03.01.530454</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.03.01.530454</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins E, Philippe E, Gravel CA, Hawken S, Langlois MA, Little J. Serological markers and long COVID&#x2013;a rapid systematic review. Eur J Clin Investig. (2023) 54:e14149. doi: 10.1111/eci.14149, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.14149</ArticleId><ArticleId IdType="pubmed">38083997</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>